Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 3Phase 3 1

Status

Unknown 3Active not recruiting 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 7NIH 1

Study Type

Interventional 8Observational 3

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 8Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Myeloid 2Dermatologic 2Classical hematology 2CNS 2Breast 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Lung Neoplasms 8Smoking Cessation 2Pulmonary Disease, Chronic Obstructive 1Motor Activity 1Inflammation 1Colorectal Neoplasms 1Cardiovascular Diseases 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Interventional × Hematologic Tests × Thoracic × Clear all
NCT06620835 2026-04-29

OPTALK

Groupe Francais De Pneumo-Cancerologie

Phase 2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms

NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting
2,000 enrolled
Thoracic

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

NCT05766046 2026-03-27

RISP

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Active not recruiting
7,324 enrolled
Thoracic

Cardiovascular Diseases, Lung Neoplasms, Smoking Cessation, Pulmonary Disease, Chronic Obstructive

NCT03645317 2021-08-02

ACCOLADE

The Christie NHS Foundation Trust

Phase NA Unknown
200 enrolled
Thoracic

Lung Neoplasms

NCT02839681 2019-05-21

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT01604642 2018-04-02

Role of Activin A (ActA) in the Human Cancer Cachexia

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase NA Completed
150 enrolled
GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT01687647 2014-04-09

AMORCE-CBP

University Hospital, Caen

Phase 3 Unknown
1,000 enrolled
Thoracic

Lung Neoplasms

NCT02090166 2014-03-18

EDLC

Carmel Medical Center

Phase NA Unknown
950 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡